Endocrine and bone complications in β -thalassemia intermedia: Current understanding and treatment

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Inati, Adlette ^a,b,c   Noureldine, Mohammadhassan A ^b   Mansour, Anthony ^b   Abbas, Hussein A ^d  

^a RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^b LEBANESE AMERICAN UNIVERSITY   (Lebanon)

^c RIZK HOSPITAL   (Lebanon)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DENOSUMAB; ESTRADIOL; FERRITIN; HEMOGLOBIN F; HYDROXYUREA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PARATHYROID HORMONE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOTATERCEPT; TESTOSTERONE; TRIACYLGLYCEROL; VITAMIN D; VITAMIN D RECEPTOR; ZOLEDRONIC ACID;

ANEMIA; ARTICLE; BETA THALASSEMIA; BETA THALASSEMIA INTERMEDIA; BLOOD TRANSFUSION; BONE DENSITY; BONE DISEASE; BONE MALFORMATION; CAUDA EQUINA SYNDROME; CESAREAN SECTION; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONGENITAL MALFORMATION; DELAYED PUBERTY; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOCRINE DISEASE; ERYTHROPOIESIS; EXTRAMEDULLARY HEMATOPOIESIS; FERRITIN BLOOD LEVEL; FERTILITY; FRACTURE; GLUCOSE INTOLERANCE; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HEMOGLOBIN BLOOD LEVEL; HEREDITY; HUMAN; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYPOTHYROIDISM; INSULIN RESISTANCE; IRON CHELATION; IRON OVERLOAD; KIDNEY FUNCTION; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PREGNANCY; PREVALENCE; SHORT STATURE; SPINAL CORD COMPRESSION; SPLENECTOMY; SPLENOMEGALY; THALASSEMIA INTERMEDIA; THROMBOEMBOLISM; THYROID GLAND; URINARY EXCRETION; BONE; COMPLICATION; PATHOLOGY;

BETA-THALASSEMIA; BONE AND BONES; ENDOCRINE SYSTEM DISEASES; HUMANS;

EID: 84925321769     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/813098     Document Type: Article

References (104)

1. J. Flint, R. M. Harding, A. J. Boyce, and J. B. Clegg, "The population genetics of the haemoglobinopathies, " Bailliere's Clinical Haematology, vol. 11, no. 1, pp. 1-51, 1998.
2. A. Taher, H. Isma'eel, and M. D. Cappellini, "Thalassemia intermedia: revisited, " Blood Cells, Molecules, and Diseases, vol. 37, no. 1, pp. 12-20, 2006.
3. N. F. Olivieri, "The-thalassemias, "The New England Journal of Medicine, vol. 341, no. 2, pp. 99-109, 1999.
4. A. Haddad, P. Tyan, A. Radwan, N. Mallat, and A. Taher, "-thalassemia intermedia: a bird's-eye view, " Turkish Journal of Hematology, vol. 31, no. 1, p. 5, 2014.
5. C. Borgna-Pignatti, "Modern treatment of thalassaemia intermedia, " British Journal of Haematology, vol. 138, no. 3, pp. 291-304, 2007.
6. M. D. Cappellini, K. M. Musallam, and A. T. Taher, "Insight onto the pathophysiology and clinical complications of thalassemia intermedia, " Hemoglobin, vol. 33, no. S1, pp. S145-S159, 2009.
7. R. Galanello and R. Origa, "Beta-thalassemia, " Orphanet Journal of Rare Diseases, vol. 5, article 11, 2010.
8. R. M. Bannerman, G. Keusch, M. Kreimer-Birnbaum, V. K. Vance, and S. Vaughan, "Thalassemia intermedia, with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyrinuria, " The American Journal of Medicine, vol. 42, no. 3, pp. 476-486, 1967.
9. A. T. Taher, K. M. Musallam, M. Karimi et al., "Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the optimal care study, " Blood, vol. 115, no. 10, pp. 1886-1892, 2010.
10. R. Origa, R. Galanello, T. Ganz et al., "Liver iron concentrations and urinary hepcidin in-thalassemia, " Haematologica, vol. 92, no. 5, pp. 583-588, 2007.
11. A. Taher, K. M. Musallam, and M. D. Cappellini, "Thalassaemia intermedia: an update, " Mediterranean Journal of Hematology and Infectious Diseases, vol. 1, no. 1, Article ID e2009004, 2009.
12. C. Peyssonnaux, A. S. Zinkernagel, R. A. Schuepbach et al., "Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs), " The Journal of Clinical Investigation, vol. 117, no. 7, pp. 1926-1932, 2007.
13. L. Silvestri, A. Pagani, and C. Camaschella, "Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis, " Blood, vol. 111, no. 2, pp. 924-931, 2008.
14. T. Tanno, N. V. Bhanu, P. A. Oneal et al., "High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin, " Nature Medicine, vol. 13, no. 9, pp. 1096-1101, 2007.
15. Z. Pakbaz, R. Fischer, E. Fung, P. Nielsen, P. Harmatz, and E. Vichinsky, "Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients, " Pediatric Blood and Cancer, vol. 49, no. 3, pp. 329-332, 2007.
16. A. Taher, F. El Rassi, H. Isma'eel, S. Koussa, A. Inati, and M. D. Cappellini, "Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia, " Haematologica, vol. 93, no. 10, pp. 1584-1586, 2008.
17. A. T. Taher, J. Porter, V. Viprakasit et al., "Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-Year results from a prospective, randomized, double-blind, placebo-controlled study, " Blood, vol. 120, no. 5, pp. 970-977, 2012.
18. A. Taher, J. Porter, and V. Viprakasit, "Estimation of liver iron concentration by serum ferritin measurement in nontransfusion-dependent thalassemia patients: analysis from the 1-year THALASSA study, " Haematologica, vol. 97, 2012.
19. K. M. Musallam, M. D. Cappellini, S. Daar, M. Karimi, A. El-Beshlawy, and A. T. Taher, "Serum ferritin levels and morbidity in beta-thalassemia intermedia: a 10-year Cohort study, " ASH Annual Meeting Abstracts, vol. 120, no. 21, p. 1021, 2012.
20. K. M. Musallam, M. D. Cappellini, and A. T. Taher, "Iron overload in-thalassemia intermedia: an emerging concern, " Current Opinion in Hematology, vol. 20, no. 3, pp. 187-192, 2013.
21. K. M. Musallam, M. D. Cappellini, J. C. Wood et al., "Elevated liver iron concentration is a marker of increased morbidity in patients with thalassemia intermedia, " Haematologica, vol. 96, no. 11, pp. 1605-1612, 2011.
22. T. G. St. Pierre, P. R. Clark, W. Chua-Anusorn et al., "Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance, " Blood, vol. 105, no. 2, pp. 855-861, 2005.
23. J. C. Wood, C. Enriquez, N. Ghugre et al., "MRI R2 and R2 mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients, " Blood, vol. 106, no. 4, pp. 1460-1465, 2005.
24. A. Taher, E. Vichinsky, K. Musallam, M. D. Cappellini, and V. Viprakasit, Guidelines for the Management of Non Transfusion DependentThalassaemia (NTDT), 2013.
25. M. G. Vogiatzi, E. A. MacKlin, F. L. Trachtenberg et al., "Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America, " British Journal of Haematology, vol. 146, no. 5, pp. 546-556, 2009.
26. V. de Sanctis, A. Tangerini, M. R. Testa et al., "Final height and endocrine function in thalassaemia intermedia, " Journal of Pediatric Endocrinology and Metabolism, vol. 11, no. 3, pp. 965-971, 1998.
27. H. Karamifar, M. Shahriari, and N. Sadjadian, "Prevalence of endocrine complications in-thalassaemiamajor in the Islamic Republic of Iran, " Eastern Mediterranean Health Journal, vol. 9, no. 1-2, pp. 55-60, 2003.
28. P. De, R. Mistry, C. Wright et al., "A review of endocrine disorders in thalassaemia, " Open Journal of Endocrine and Metabolic Diseases, vol. 4, no. 2, pp. 25-34, 2014.
29. V. De Sanctis, A. Eleftheriou, and C. Malaventura, "Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF), " Pediatric Endocrinology Reviews, vol. 2, no. 2, pp. 249-255, 2004.
30. J. Papadimas, D. G. Goulis, E. Mandala et al., "B-thalassemia and gonadal axis: a cross-sectional, clinical study in a Greek population, " Hormones, vol. 1, no. 3, pp. 179-187, 2002.
31. M. R. Gamberini, V. de Sanctis, and G. Gilli, "Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: Incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from1980 to 2007 in the Ferrara centre, " Pediatric Endocrinology Reviews, vol. 6, no. 1, pp. 158-169, 2008.
32. M. J. Cunningham, E. A. Macklin, E. J. Neufeld, and A. R. Cohen, "Complications of-thalassemia major in North America, " Blood, vol. 104, no. 1, pp. 34-39, 2004.
33. C. Savona-Ventura and E. Grech, "Pregnancy complications in homozygous thalassaemia patients, " Journal of Obstetrics and Gynaecology, vol. 11, no. 3, pp. 175-176, 1991.
34. M. Toumba, A. Sergis, C. Kanaris, and N. Skordis, "Endocrine complications in patients with Thalassaemia Major, " Pediatric Endocrinology Reviews, vol. 5, no. 2, pp. 642-648, 2007.
35. S. M. Tuck, C. E. Jensen, B. Wonke, and A. Yardumian, "Pregnancymanagement and outcomes in women with thalassaemia major, " Journal of Pediatric Endocrinology and Metabolism, vol. 11, no. 3, pp. 923-928, 1998.
36. R. Origa, A. Piga, G. Quarta et al., "Pregnancy and-thalassemia: an Italian multicenter experience, " Haematologica, vol. 95, no. 3, pp. 376-381, 2010.
37. E. A. Rachmilewitz and P. J. Giardina, "How I treat thalassemia, " Blood, vol. 118, no. 13, pp. 3479-3488, 2011.
38. N. Skordis, S. Christou, M. Koliou, N. Pavlides, and M. Angastiniotis, "Fertility in female patients with thalassemia, " Journal of Pediatric Endocrinology and Metabolism, vol. 11, supplement 3, pp. 935-943, 1998.
39. A. H. Nassar, I. M. Usta, J. B. Rechdan, S. Koussa, A. Inati, and A. T. Taher, "Pregnancy in patients with-thalassemia intermedia: outcome of mothers and newborns, " The American Journal of Hematology, vol. 81, no. 7, pp. 499-502, 2006.
40. A. H. Nassar, I. M. Usta, and A. M. Taher, "-Thalassemia intermedia and pregnancy: shouldwe anticoagulate" Journal of Thrombosis and Haemostasis, vol. 4, no. 6, pp. 1413-1414, 2006.
41. A. H. Nassar, M. Naja, C. Cesaretti, B. Eprassi, M. D. Cappellini, and A. Taher, "Pregnancy outcome in patients with-thalassemia intermedia at two tertiary care centers, in Beirut and Milan, " Haematologica, vol. 93, no. 10, pp. 1586-1587, 2008.
42. A. T. Taher, K. M. Musallam, M. D. Cappellini, and D. J. Weatherall, "Optimal management of thalassaemia intermedia, " British Journal of Haematology, vol. 152, no. 5, pp. 512-523, 2011.
43. F. Mojtahedzadeh, M. Kosaryan, M.-R. Mahdavi, and J. Akbari, "The effect of folic acid supplementation in beta-thalassemia major: a randomized placebo-controlled clinical trial, " Archives of Iranian Medicine, vol. 9, no. 3, pp. 266-268, 2006.
44. A. Kurtoglu, E. Kurtoglu, and A. K. Temizkan, "Effect of iron overload on endocrinopathies in patients with betathalassaemia major and intermedia, " Endokrynologia Polska, vol. 63, no. 4, pp. 260-263, 2012.
45. J. P. S. Chern, K. H. Lin, M. Y. Lu et al., "Abnormal glucose tolerance in transfusion-dependent-thalassemic patients, " Diabetes Care, vol. 24, no. 5, pp. 850-854, 2001.
46. L. Monge, S. Pinach, L. Caramellino, M. T. Bertero, A. Dall'Omo, and Q. Carta, "The possible role of autoimmunity in the pathogenesis of diabetes in-thalassemia major, " Diabetes and Metabolism, vol. 27, no. 2 I, pp. 149-154, 2001.
47. M. I. Argyropoulou, D. N. Kiortsis, L. Astrakas, Z. Metafratzi, N. Chalissos, and S. C. Efremidis, "Liver, bone marrow, pancreas and pituitary gland iron overload in young and adult thalassemic patients: a T2 relaxometry study, " European Radiology, vol. 17, no. 12, pp. 3025-3030, 2007.
48. L. J. Noetzli, S. D. Mittelman, R. M. Watanabe, T. D. Coates, and J. C. Wood, "Pancreatic iron and glucose dysregulation in thalassemiamajor, " American Journal ofHematology, vol. 87, no. 2, pp. 155-160, 2012.
49. M. R. Gamberini, M. Fortini, V. de Sanctis, G. Gilli, and M. R. Testa, "Diabetes mellitus and impaired glucose tolerance in thalassaemia major: incidence, prevalence, risk factors and survival in patients followed in the Ferrara Center, " Pediatric Endocrinology Reviews, vol. 2, no. 2, pp. 285-291, 2004.
50. I. Rotaur, A. Gaman, and G. Gaman, "Secondary haemochromatosis in a patient with thalassemia intermedia, " Current Health Sciences Journal, vol. 40, no. 1, pp. 67-70, 2014.
51. W.-Y. Au, W. W.-M. Lam, W. Chu et al., "A T2 magnetic resonance imaging study of pancreatic iron overload in thalassemia major, " Haematologica, vol. 93, no. 1, pp. 116-119, 2008.
52. R. A. De Assis, A. A. F. Ribeiro, F. U. Kay et al., "Pancreatic iron stores assessed by magnetic resonance imaging (MRI) in beta thalassemic patients, " European Journal of Radiology, vol. 81, no. 7, pp. 1465-1470, 2012.
53. K. Farmaki, N. Angelopoulos, G. Anagnostopoulos, E. Gotsis, G. Rombopoulos, and G. Tolis, "Effect of enhanced iron chelation therapy on glucose metabolism in patients with-thalassaemiamajor, " British Journal ofHaematology, vol. 134, no. 4, pp. 438-444, 2006.
54. C. Hartman, H. Tamary, A. Tamir et al., "Hypocholesterolemia in children and adolescents with-thalassemia intermedia, "The Journal of Pediatrics, vol. 141, no. 4, pp. 543-547, 2002.
55. S. M. Altamentova, E. Marva, and N. Shaklai, "Oxidative interaction of unpaired hemoglobin chains with lipids and proteins: a key for modified serum lipoproteins in thalassemia, " Archives of Biochemistry and Biophysics, vol. 345, no. 1, pp. 39-46, 1997.
56. S. Haghpanah, M. Davani, B. Samadi, A. Ashrafi, and M. Karimi, "Serum lipid profiles in patients with beta-thalassemia major and intermedia in southern Iran, " Journal of Research inMedical Sciences, vol. 15, no. 3, pp. 150-154, 2010.
57. M. Maioli, G. B. Cuccuru, P. Pranzetti, A. Pacifico, and G. M. Cherchi, "Plasma lipids and lipoproteins pattern in betathalassemia major, " Acta Haematologica, vol. 71, no. 2, pp. 106-110, 1984.
58. M. Maioli, G. B. Vigna, G. Tonolo et al., "Plasma lipoprotein composition, apolipoprotein(a) concentration and isoforms in-thalassemia, " Atherosclerosis, vol. 131, no. 1, pp. 127-133, 1997.
59. G. Amendola, P. Danise, N. Todisco, G. D'Urzo, A. di Palma, and R. di Concilio, "Lipid profile in-thalassemia intermedia patients: correlation with erythroid bone marrow activity, " International Journal of Laboratory Hematology, vol. 29, no. 3, pp. 172-176, 2007.
60. A. Aessopos, M. Kati, and J. Meletis, "Thalassemia intermedia today: should patients regularly receive transfusions" Transfusion, vol. 47, no. 5, pp. 792-800, 2007.
61. L. Tesoriere, D. D'Arpa, A. Maggio, V. Giaccone, E. Pedone, and M. A. Livrea, "Oxidation resistance of LDL is correlated with vitamin E status in-thalassemia intermedia, " Atherosclerosis, vol. 137, no. 2, pp. 429-435, 1998.
62. L. Tesoriere, D. D'Arpa, D. Butera et al., "Oral supplements of vitamin E improve measures of oxidative stress in plasma and reduce oxidative damage to LDL and erythrocytes in-thalassemia intermedia patients, " Free Radical Research, vol. 34, no. 5, pp. 529-540, 2001.
63. A. Mehrvar, A. Azarkeivan, M. Faranoush et al., "Endocrinopathies in patients with transfusion-dependent-thalassemia, " Pediatric Hematology and Oncology, vol. 25, no. 3, pp. 187-194, 2008.
64. V. de Sanctis, E. de Sanctis, P. Ricchieri, E. Gubellini, G. Gilli, and M. R. Gamberini, "Mild subclinical hypothyroidism in thalassaemia major: prevalence, multigated radionuclide test, clinical and laboratory long-term follow-up study, " Pediatric Endocrinology Reviews, vol. 6, no. 1, pp. 174-180, 2008.
65. K. Farmaki, I. Tzoumari, C. Pappa, G. Chouliaras, and V. Berdoukas, "Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major, " British Journal of Haematology, vol. 148, no. 3, pp. 466-475, 2010.
66. O. R. Zekavat, A. R. Makarem, S. Haghpanah, Z. Karamizadeh, P. Javad, and M. Karimi, "Hypothyroidism in-thalassemia intermedia patients with and without Hydroxyurea, " Iranian Journal of Medical Sciences, vol. 39, no. 1, pp. 60-63, 2014.
67. D. Bisbocci, C. Camaschella, D. Sperone, P. Livorno, M. Gambino, and P. Modina, "Hypothalamic pituitary adrenal function in patients with thalassemia major, " Recenti Progressi in Medicina, vol. 80, no. 10, pp. 551-556, 1989.
68. V. C. Canale, P. Steinherz, M. New, M. Erlandson, "Endocrine function in thalassemia major Annals of the New York Academy of Sciences 232, 333-345, 1974.
69. A. Masala, T. Meloni, D. Gallisai et al., "Endocrine functioning in multitransfused prepubertal patients with homozygous-thalassemia, " Journal of Clinical Endocrinology andMetabolism, vol. 58, no. 4, pp. 667-670, 1984.
70. G. Costin, M. D. Kogut, C. B. Hyman, and J. A. Ortega, "Endocrine abnormalities in thalassemia major, " American Journal of Diseases of Children, vol. 133, no. 5, pp. 497-502, 1979.
71. N. McIntosh, "Endocrinopathy in thalassaemia major, " Archives of Disease in Childhood, vol. 51, no. 3, pp. 195-201, 1976.
72. C. Pintor, S. Loche, A. Faedda et al., "Sexual maturation and adrenal function in girls with thalassemia, " Journal of Endocrinological Investigation, vol. 7, no. 3, pp. 181-184, 1984.
73. C. Pintor, S. Loche, R. Puggioni et al., "Adrenal and testicular function in boys affected by thalassemia, " Journal of Endocrinological Investigation, vol. 7, no. 2, pp. 147-149, 1984.
74. K. E. Huang, S. D. Mittelman, T. D. Coates, M. E. Geffner, and J. C. Wood, "A significant proportion of thalassemia major patients have adrenal insufficiency detectable on provocative testing, " Journal of Pediatric Hematology/Oncology. In press.
75. N. McIntosh, "Threshold adrenocortical function in children with thalassaemia, " Journal of Endocrinology, vol. 68, no. 1, pp. 159-160, 1976.
76. S. Perrotta, M. D. Cappellini, F. Bertoldo et al., "Osteoporosis in-thalassaemia major patients: analysis of the genetic background, " The British Journal of Haematology, vol. 111, no. 2, pp. 461-466, 2000.
77. B. Wonke, "Bone disease in-thalassaemia major, " British Journal of Haematology, vol. 103, no. 4, pp. 897-901, 1998.
78. E. Voskaridou and E. Terpos, "New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia, " British Journal of Haematology, vol. 127, no. 2, pp. 127-139, 2004.
79. R. D. Pollak, E. Rachmilewitz, A. Blumenfeld, M. Idelson, and A. W. Goldfarb, "Bone mineral metabolism in adults with-thalassaemia major and intermedia, " British Journal of Haematology, vol. 111, no. 3, pp. 902-907, 2000.
80. J. A. Kanis, "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of aWHO report, " Osteoporosis International, vol. 4, no. 6, pp. 368-381, 1994.
81. E. Voskaridou, M.-C. Kyrtsonis, E. Terpos et al., "Bone resorption is increased in young adults with thalassaemia major, " British Journal of Haematology, vol. 112, no. 1, pp. 36-41, 2001.
82. M. Hashemieh, A. Azarkeivan, M. Radfar et al., "Prevalence of osteoporosis among thalassemia patients from Zafar adult thalassemia clinic, Iran, " Iranian Journal of Blood and Cancer, vol. 6, no. 3, pp. 143-148, 2014.
83. M. Karimi, A. F. Ghiam, A. Hashemi, S. Alinejad, M. Soweid, and S. Kashef, "Bone mineral density in beta-thalassemiamajor and intermedia, " Indian Pediatrics, vol. 44, no. 1, pp. 29-32, 2007.
84. M. Angastiniotis, N. Pavlides, K. Aristidou et al., "Bone pain in thalassaemia: assessment of DEXA and MRI findings, " Journal of Pediatric Endocrinology and Metabolism, vol. 11, no. 3, pp. 779-784, 1998.
85. V. Ladis, P. Raptou, E. Rigatou et al., "Study of bone density by pQCT analysis in healthy adults and patients with Bthalassemia major and intermedia, " Pediatric Endocrinology Reviews, vol. 6, no. 1, pp. 127-131, 2008.
86. L. G. Raisz, "Therapeutic options for the patientwith osteoporosis, " The Endocrinologist, vol. 1, no. 1, pp. 11-18, 1991.
87. E. Carmina, G. di Fede, N. Napoli et al., "Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major, " Calcified Tissue International, vol. 74, no. 1, pp. 68-71, 2004.
88. Y. Boutsen, J. Jamart, W. Esselinckx, and J. P. Devogelaer, "Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3months, and calciumalone, " Journal of Bone andMineral Research, vol. 16, no. 1, pp. 104-112, 2001.
89. C. Brumsen, S. E. Papapoulos, P. Lips et al., "Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension, " Journal of Bone and Mineral Research, vol. 17, no. 6, pp. 1057-1064, 2002.
90. G. L. Forni, S. Perrotta, A. Giusti et al., "Neridronate improves bone mineral density and reduces back pain in-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study, " British Journal of Haematology, vol. 158, no. 2, pp. 274-282, 2012.
91. E. Voskaridou, A. Anagnostopoulos, K. Konstantopoulos et al., "Zoledronic acid for the treatment of osteoporosis in patients with-thalassemia: results from a single-center, randomized, placebo-controlled trial, " Haematologica, vol. 91, no. 9, pp. 1193-1202, 2006.
92. E. Voskaridou, E. Terpos, G. Spina et al., "Pamidronate is an effective treatment for osteoporosis in patients with betathalassaemia, " British Journal ofHaematology, vol. 123, no. 4, pp. 730-737, 2003.
93. E. Voskaridou, D. Christoulas, L. Antoniadou, and E. Terpos, "Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis, " Acta Haematologica, vol. 119, no. 1, pp. 40-44, 2008.
94. N. Raje and S. Vallet, "Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss, " Current Opinion in Molecular Therapeutics, vol. 12, no. 5, pp. 586-597, 2010.
95. M. E. Erlandson, R. Brilliant, and C. H. Smith, "Comparison of sixty-six patients with thalassemia major and thirteen patients with thalassemia intermedia: including evaluations of growth, development, maturation and prognosis, " Annals of the New York Academy of Sciences, vol. 119, pp. 727-735, 1964.
96. M. G. Vogiatzi, E. A. Macklin, E. B. Fung et al., "Prevalence of fractures among the Thalassemia syndromes in North America, " Bone, vol. 38, no. 4, pp. 571-575, 2006.
97. C. Camaschella and M. D. Cappellini, "Thalassemia intermedia, " Haematologica, vol. 80, no. 1, pp. 58-68, 1995.
98. S. Prabhakar, J. S. Chopra, V. K. Khosla, S. Dash, and A. K. Banerjee, "Spinal cord compression in homozygous beta thalassaemia, " Surgical Neurology, vol. 13, no. 5, pp. 351-354, 1980.
99. E. Coskun, A. Keskin, T. Süzer, Y. Sermez, T. Kildaci, and K. Tahta, "Spinal cord compression secondary to extramedullary hematopoiesis in thalassemia intermedia, " European Spine Journal, vol. 7, no. 6, pp. 501-504, 1998.
100. N. Khandelwal, N. Malik, V. K. Khosla, and S. Suri, "Spinal cord compression due to epidural extramedullary haematopoiesis in thalassemia, " Pediatric Radiology, vol. 22, no. 1, pp. 70-71, 1992.
101. G. Chaljub, F. C. Guinto Jr., W. N. Crow, and R. Kumar, "Briefly noted: MRI diagnosis of spinal cord compression in betathalassemia, " Spine, vol. 16, no. 5, pp. 583-584, 1991.
102. A. Guermazi, Y. Miaux, and J. Chiras, "Imaging of spinal cord compression due to thoracic extramedullary haematopoiesis in myelofibrosis, " Neuroradiology, vol. 39, no. 10, pp. 733-736, 1997.
103. E. G. Singounas, D. E. Sakas, D. M. Hadley et al., "Paraplegia in a pregnant thalassemic woman due to extramedullary hematopoiesis: successful management with transfusions, " Surgical Neurology, vol. 36, no. 3, pp. 210-215, 1991.
104. H. Cario, M. Wegener, K.-M. Debatin, and E. Kohne, "Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis, " Annals of Hematology, vol. 81, no. 8, pp. 478-482, 2002.